

# If you have patients diagnosed with CIDP,

currently prescribed but not yet started treatment with **efgartigimod/Vyvgart® Hytrulo**, consider referring them to this real-world evidence (RWE) study.



**ADHERE REAL** is a prospective, real-world, observational study designed to understand how adults with CIDP respond to treatment with **Vyvgart® Hytrulo** in everyday clinical practice. We are inviting adults diagnosed with CIDP who are about to start **Vyvgart® Hytrulo** to participate. The study is remote, with periodic electronic questionnaires and scheduled home- or tele-visit assessments. By sharing their treatment experiences, symptoms, and quality-of-life information over time, participants will help generate valuable real-world insights that may improve future care for people living with CIDP.

Adults diagnosed with CIDP who are about to start treatment with **Vyvgart® Hytrulo** may be eligible. Participation is completely voluntary and will not affect the care or support they receive. Participation includes completing periodic online questionnaires over time, with some clinical assessments conducted remotely or by trained nurses.



Scan the QR code to get started.

For more information go to  
**CIDPResearchStudy.com**